We are excited to announce that the FDA has cleared our investigational new drug (IND) application for DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) associated with menopause.

Daré Bioscience Placed #1 in the Small Company Category of the San Diego Business Journal’s “2023 Best Places to Work” (Subscription required)